Sign In
Section Navigation
Common TitleTMB-301
Official Title A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1
Phase Phase III
ClinicalTrials.gov NCT02475629
Treatments
Ibalizumab
Ibalizumab Trogarzo

Ibalizumab

Tradename:TrogarzoOther Names:IBAClass:Entry Inhibitors
Categories Resistance/Virological FailureTreatment-Experienced
Funding
IndustryTaiMed Biologics Inc.
References
  • Emu B, Fessel J, Schrader S, et al. Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1. N Engl J Med. 2018;379:645-54.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.